Status
Conditions
Treatments
About
This is a prospective, cohort study in Faculty of Medicine, Zagazig University, Egypt. From June to December, 2016, investigators will follow up patients with chronic Hepatitis C virus genotype 4 receiving daclatasvir-sofosbuvir treatment regimen within the national program of Egyptian ministry of health and population. The primary outcomes are safety of the treatment and the sustained virologic response 12 weeks after discontinuation of therapy. For the secondary outcomes, investigators will measure the change in health related quality of life and investigate the genetic sequence of viral RNA of resistant patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
250 participants in 3 patient groups
Loading...
Central trial contact
Hussien Ahmed, MD; Ahmed Negida
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal